A phase II trial of low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic melanoma

This LTBI and IL-2 regimen was well tolerated, however it cannot be recommended because of its low clinical efficacy. No indication of increased efficacy or altered toxicity was seen using LTBI.